SCHEMBL2850811

SCHEMBL2850811

CN1CC(=O)Nc2ccc(Cl)cc2C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
TGM2 P21980 2/20 0.47
CES1 P23141 1/20 0.47
AHR P35869 2/20 0.46
CNR1 P21554 1/20 0.45
NTSR1 P30989 1/20 0.45
OPRK1 P41145 1/20 0.45
PDE4D Q08499 1/20 0.45
GABRG2 P18507 5/20 0.44
GABRB3 P28472 5/20 0.44
GABRA5 P31644 5/20 0.44
GABRA1 P14867 4/20 0.44
GABRA3 P34903 4/20 0.44
GABRA2 P47869 4/20 0.44
GABRA6 Q16445 4/20 0.44
GABRA4 P48169 3/20 0.44
GABRP O00591 2/20 0.44
GABRD O14764 2/20 0.44
GABRB1 P18505 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11686737 0.85 MEN1 (0.50) MEN1KMT2ATGM2CES1GABRG2
SCHEMBL435141 0.83 MEN1 (0.70) MEN1KMT2ALRRK2LMNA
SCHEMBL29676340 0.81 KMT2A (0.68) MEN1KMT2AGABRG2GABRB3GABRA5
SCHEMBL14610310 0.81 MEN1 (0.68) MEN1KMT2ANPC1CYP3A4GRM5
SCHEMBL11028170 0.81 MEN1 (0.73) MEN1KMT2AGABRG2GABRB3GABRA5
SCHEMBL7138979 0.81 KMT2A (0.68) MEN1KMT2AGABRG2GABRB3GABRA5
SCHEMBL14114321 0.81 MEN1 (0.68) MEN1KMT2ATGM2CES1GABRG2
SCHEMBL11027733 0.81 MEN1 (0.68) MEN1KMT2ANPC1RAB9A
SCHEMBL7271469 0.81 KMT2A (1.00) MEN1KMT2ATGM2CES1AHR
SCHEMBL13150265 0.81 CYP11B1 (0.53) MEN1KMT2AAHRCMA1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130479-A1 Gabaergic Agents to Treat Memory Deficits NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-05-27 US disclosed
US-20100130479-A1 Gabaergic Agents to Treat Memory Deficits NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-05-27 US disclosed
US-20100130479-A1 Gabaergic Agents to Treat Memory Deficits NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-05-27 US disclosed
US-7595395-B2 Gabaergic agents to treat memory deficits WISYS TECHNOLOGY FOUNDATION (US) 2009-09-29 US disclosed
US-7595395-B2 Gabaergic agents to treat memory deficits WISYS TECHNOLOGY FOUNDATION (US) 2009-09-29 US disclosed
US-7595395-B2 Gabaergic agents to treat memory deficits WISYS TECHNOLOGY FOUNDATION (US) 2009-09-29 US disclosed
EP-1888594-A2 GABAERGIC AGENTS TO TREAT MEMORY DEFICITS WISYS TECHNOLOGY FOUNDATION, INC. (US) 2008-02-20 EP disclosed
WO-2007018660-A2 GABAERGIC IMIDAZOBENZODIAZEPINE DERIVATIVES TO TREAT MEMORY DEFICITS WISYS TECHNOLOGY FOUNDATION, INC. (US) 2007-02-15 WO disclosed
WO-2007018660-A2 GABAERGIC IMIDAZOBENZODIAZEPINE DERIVATIVES TO TREAT MEMORY DEFICITS WISYS TECHNOLOGY FOUNDATION, INC. (US) 2007-02-15 WO disclosed
US-20060258643-A1 GABAERGIC AGENTS TO TREAT MEMORY DEFICITS WISYS TECHNOLOGY FOUNDATION, INC. (US) 2006-11-16 US disclosed
US-4346032-A ANTIDOTES TO OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4346034-A Process for preparing imidazodiazepines HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4346031-A Process for preparing imidazodiazepines HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4346036-A ALKYLATION; AMIDATION; TRANQUILIZER ANTAGONIST HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4316839-A Imidazodiazepine derivatives HOFFMAN-LA ROCHE INC. (US) 1982-02-23 US disclosed
EP-0027214-A1 Imidazodiazepine derivatives, process and intermediates for their preparation, medicaments containing them and their therapeutic application F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-04-22 EP disclosed
US-4031079-A Intermediates for 2-aminobenzodiazepine-5-ones MCNEIL LABORATORIES, INCORPORATED (US) 1977-06-21 US disclosed
US-4022767-A 2-Aminobenzodiazepine-5-ones MCNEIL LABORATORIES, INCORPORATED (US) 1977-05-10 US disclosed
US-4020055-A Intermediates for 2-aminobenzodiazepine-5-ones MCNEIL LABORATORIES, INCORPORATED (US) 1977-04-26 US disclosed
US-4002610-A 2-Aminobenzodiazepine-5-ones MCNEIL LABORATORIES, INCORPORATED (US) 1977-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130479-A1 Gabaergic Agents to Treat Memory Deficits GABRA5, GABRA6, GABRB1 MEN1 3247/4885KMT2A 396/4885TGM2 1025/4885
US-20060258643-A1 GABAERGIC AGENTS TO TREAT MEMORY DEFICITS GABRA5, GABRA6, GABRA1 MEN1 2769/4885KMT2A 336/4885TGM2 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.